Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Ferumoxytol vs Placebo in CKD Anemia
NCT00255450Phase 3Completed
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Jan 2005
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ferumoxytol in anemia (2 arms), sponsored by AMAG Pharmaceuticals, Inc. Primary endpoint: Safety evaluated by physical examinations, vital signs, laboratory tests and patient monitoring and evaluation. Started Jan 2005; status: completed.
02
Drugs
ferumoxytol
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00255450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255450.